Stock CHRS COHERUS BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Real-time Estimate Cboe BZX
Other stock markets
 03:50:33 2024-05-10 pm EDT 		5-day change 1st Jan Change
1.885 USD -11.08% Intraday chart for Coherus BioSciences, Inc. -19.38% -45.05%
May. 09 Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, vs. Street Est of $83.8M MT
May. 09 Coherus BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, vs. Street Est of $83.8M
MT
Coherus BioSciences: Q1 Earnings Snapshot
AQ
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Coherus BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI with ENB Therapeutics ENB-003 for the Treatment of Ovarian Cancer
AQ
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
GL
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
AQ
Coherus Biosciences, Inc. Enters into a Senior Secured Term Loan Facility
CI
Coherus BioSciences, Inc. Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
CI
Coherus BioSciences, Inc. announced that it has received $38.7 million in funding
CI
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
GL
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
AQ
Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer
CI
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
GL
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting
CI
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
GL
HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CHRS Stock
  4. News Coherus BioSciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW